Mumbai police order CCTV cameras at medical stores in a month to curb illegal drug sales
Mumbai police
has asked all pharmacy stores to install CCTV cameras in their premises within a month.
Owners of medical stores and chemist shops are unhappy with the move as they believe such measures will not help.
Scheduled drugs refer to medications regulated under the Drugs and Cosmetics Rules, 1945, on the basis of how they are manufactured, stored, distributed, and prescribed. For instance, Schedule H includes prescription drugs that cannot be sold without a doctor's prescription and Schedule X refers to prescription drugs that are highly addictive
You Can Also Check:
Mumbai AQI
|
Weather in Mumbai
|
Bank Holidays in Mumbai
|
Public Holidays in Mumbai
The directive, issued under Section 152 of the Indian Civil Security Code, 2023, by deputy commissioner of police (anti-narcotics cell) Navnath Dhawale, is based on intelligence inputs.
The Narcotics Control Bureau (NCB) and the Commission for Protection of Child Rights, New Delhi, too, had recently raised concerns about the sale of scheduled drugs and inhalants without valid prescriptions.
The Anti-Narcotics Cell and Food and Drug Administration (FDA) found several medical stores in Mumbai sold habit-forming drugs without maintaining proper records.
According to the order, every medical shop in Mumbai and its suburban districts will have to install CCTV cameras at all entrances, exits, and sale counters in such a way that the faces of customers and transactions are recorded.
The cameras must have a minimum resolution of 2 megapixels, and footage must be stored for at least one month. Officials from the District Drug Control Authority and Child Welfare Police Officers can inspect CCTV footage.
Medical shop owners have been given a 30-day period to comply with the order. Senior officials said the initiative is part of a larger crackdown on the misuse of prescription drugs, often diverted into the narcotics trade.
Abay Pandey, president of the All Food and License Holders Foundation, told TOI: "Firstly, the police have no powers to check medical stores if there are not accompanied by FDA officials. Secondly, these CCTV cameras won't serve any purpose as the prescriptions and medicine strips are written in small fonts. How is the camera going to help them?"
Prasad Danave, president of Retail and Dispensing Chemist Association Mumbai, said, "How is the camera going to keep a tab on the medicines sold? What about the online sites that sell abortion pills to a 14-year-old girl? Is there any check on them?"
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
7 hours ago
- Mint
India's booming beauty industry has a serious problem of quality. New rules target this menace
New Delhi: India has tightened rules to ensure stricter testing and labelling of cosmetics to enhance safety, check counterfeit products and clearly define spurious items, said two officials aware of the development. A failure to comply with the new rules introduced by the health and family welfare ministry will result in the suspension and cancellation of licences, according to the officials cited earlier and documents reviewed by Mint. The Cosmetics (Amendment) Rules, 2025 were finalized and notified on 29 July after a detailed consultative process with the relevant stakeholders and further consultation with the Drugs Technical Advisory Board, a top drug advisory panel, said the first official quoted earlier. The changes include setting up a dedicated Central Cosmetics Laboratory to test products before they hit the shelves. India's cosmetics market—including skin, hair and oral care, fragrances, and colour products—is estimated at $20 billion, growing at an annualized rate of 25%, according to India Brand Equity Foundation. New brands have been mushrooming as rising incomes spur consumption. However, that also brought a myriad of new products claiming to provide unverified benefits, especially when peddled by celebrities and influencers. Stricter rules aim to curb exaggerated claims and ensure higher standards that will also benefit exports. "The cosmetic industry in India is largely under-regulated, particularly concerning product claims. Unlike in many other countries, companies here can make unsubstantiated assertions—such as promising to make a person several shades fairer or claiming to stop hair fall—that are often misleading,' said Dr Dinesh Kumar Devaraj, president, Indian Association of Dermatologists, Venereologists & Leprologists (IADVL), Tamil Nadu. 'This is where regulatory checks are critically needed.' Queries sent to the health ministry spokesperson and cosmetic manufacturers, including Hindustan Unilever Ltd, on Friday remained unanswered. Cosmetics in India are regulated under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) is the main regulatory body responsible for implementing the rules. 'Lots of clerical and administrative corrections have been made in cosmetics rules,' the first official quoted earlier said. 'These comprehensive measures signal a serious commitment by the government to prioritize consumer safety and bring greater transparency to India's cosmetics industry.' Manufacturers will now have to keep detailed records of all raw materials and manufactured batches for three years or six months after the batch expires, whichever is later. This improved record-keeping will significantly enhance the traceability of products in case of a safety concern. The new regulations require that labels on cosmetics to be exported meet the legal standards of the destination country. A cornerstone of the new policy is the Central Cosmetics Laboratory to test samples. It will also be an appellate laboratory, ensuring a centralized and rigorous approach to product quality. The rules, for the first time, empower the State Licensing Authority to suspend or cancel a license if a company fails to comply with any of its conditions or with any provision of the Act or the rules. This order will be issued in writing after giving the licencee an opportunity to show cause and be heard. However, a manufacturer whose licence is suspended or cancelled has the right to appeal the decision to the state government within 90 days, ensuring due process is followed. The new regulations specifically define 'spurious cosmetics' under section 17D of the Act, strengthening the government's ability to crack down on counterfeit items. That provides a stronger legal basis for regulatory bodies to crack down on such items. The rules also seek to streamline international trade. 'The cosmetic is meant for export, then the label on the package or container of cosmetic shall comply with the law of the country to which the cosmetic is to be exported,' the notification said. Similarly, a specific provision has been added to allow for a code number instead of the manufacturer's name and address on the label if the importer requires it. These changes are designed to protect consumers from unsafe and counterfeit cosmetic products while strengthening the regulatory framework, the second official quoted earlier said. According to the L'Oréal India spokesperson, the updated cosmetic regulations enhance clarity and compliance, '…particularly the provision for export labelling, which significantly streamlines international trade, benefiting our exports from India to 25 countries'. Citing that 95% of its products sold in India are locally manufactured, the spokesperson said these 'progressive changes further support our 'Make in India' endeavors and our mission to provide high-quality beauty solutions both domestically and internationally'. The industry has also come under scrutiny after complaints regarding mercury-based products, Mint reported earlier. Products such as skin-lightening creams, 'anti-ageing solutions' for freckles and dark spots and certain makeup items are known to contain the toxic element. Dr. Devaraj said another concern is the misuse of steroids in cosmetics for skin brightening, which can lead to significant dermatological damage. 'As a doctor, I can easily distinguish between skin that has been brightened by such steroid use and skin that is healthy,' he said. 'The issue of wrong or non-existent labelling also needs to be addressed. Furthermore, there is a complete lack of regulation on pricing, which allows for a dramatic disparity in costs for similar products.' The validation provided by celebrities and social media influencers heavily influences consumers, especially first-time buyers, according to him. 'Given our vast population, a small fraction of buyers can generate significant profit for a company, reducing the need for repeat business,' said Dr. Devaraj. 'This trend has been amplified by the rise in online sales and paid promotions post-Covid.'
Hindustan Times
13 hours ago
- Hindustan Times
FDA recalls butter across US: What Class II warning means, which product has been recalled
Beware while buttering your toasts as the U.S. Food and Drug Administration (FDA) recently escalated a nationwide butter recall to Class II, a higher risk level. The butter recall for 64,800 lbs (or 1,800 cases) was initially issued by Bunge North America Inc. Image for representation(Pixabay) The risk classification was raised by the FDA on Wednesday, July 30. Why was butter recall issued and who is to blame? The butter recall for 64,800 lbs (or 1,800 cases) was issued by Bunge North America Inc, which is based out of Chesterfield, Missouri. The product that has been recalled is its European Style Butter Blend 1 lb. The voluntary recall came on July 14, and has now been escalated by the government entity. The company said it was recalling the product because milk was undeclared and not listed on the product label. The lot code number for the butter is 5064036503. Milk is one of the nine food allergens as per the FDA site. Food-related allergies can vary in symptoms ranging from face and lip swelling to vomiting. However, there is also the risk of severe reactions like anaphylaxis, where the immune system could release a 'flood of chemicals' which could make a person go into shock and end up being fatal for them, Mayo Clinic said. As per the FDA, they enforce regulations to avoid such situations and they said there are 'more specific labeling requirements' for foods that can cause allergies and other hypersensitive reactions. What does FDA's Cass II warning mean? As per the FDA site, a Class II recall indicates 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote'. They advised people, that if anyone has consumed the product and starts to feel something is not right, they should 'stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine) and seek medical attention.'
Hindustan Times
14 hours ago
- Hindustan Times
NDPS case: Panchkula court junks anticipatory bail plea of 3 pharmacists
A local court has dismissed the anticipatory bail pleas of three Panchkula pharmacists who were caught selling psychotropic tablets to an unauthorised purchaser in February this year. The court of additional sessions judge Himanshu Singh junked the plea after the NCB stated that their custodial interrogation was required. (Shutterstock) The accused are Ashish Gupta, 33, the proprietor of M/s Hare Krishna Pharma, Jatinder Verma, 51, of M/s Verma Medico Distributors and Amit Chopra, 45, of M/s UR Enterprises The case dates back to February 28 when a team, acting on CBI intelligence, inspected Pinjore-based M/s Deep Medicos, and found psychotropic tablets being sold without permit. The matter was handed over to Narcotics Control Bureau (NCB), Chandigarh, which seized 948 tablets/capsules and registered a case against proprietor Randeep Singh based on his voluntary, self-incriminatory statement. In his statement, Randeep named wholesale dealers Ashish Gupta, Jatinder Verma and Amit Chopra. Based on this, the NCB registered a case against them for violating their licence conditions by selling psychotropic substances to an unauthorised purchaser, M/s Deep Medicos. The court of additional sessions judge Himanshu Singh junked the plea after the NCB stated that their custodial interrogation was required. Last week, the court had dismissed the bail plea of other pharmacists involved in the case: Sanjay Kumar, 61, of M/s SS Bharti, Naresh Kumar Sardana, 54, of M/s Mediking, and Deepak Sharma, 55, of Sharma Enterprises.
